Trade Name: SODIUM IODIDE I 123

Following information is meant for : Wholesalers, Suppliers, Exporters, Doctors, CROs, Comparator Supplies, Hospitals, MOH Tender Supplies, Generic, Brand, Cooperate Sourcing, India, Institutional Buyers.

Manufacturer: Curium US LLC

Presentation: CAPSULE, GELATIN COATED, HUMAN PRESCRIPTION DRUG

Strength: 100 uCi/1

Storage and handling

SODIUM IODIDE I-123

Disclaimer:
  1. These products are NOT FOR SALE in US territories. We offer them for Exports outside of US Territories to Trade Professionals or patients with a valid prescription.
  2. Trademark shown are property of their respective owners and GNH India does not lay any claim on them.
  3. Read more
  • No data
  • Sodium Iodide I 123 (NaI) for diagnostic use is supplied in capsules for oral administration. The capsules are available in strengths of 3.7 and 7.4 megabecquerels (MBq) (100 and 200 u03bcCi) I-123 at time of calibration.
  • The radionuclidic composition at calibration is not less than 97.0 percent I-123, not more than 2.9 percent I-125 and not more than 0.1 percent Te-121. The radionuclidic composition at expiration time is not less than 87.2 percent I-123, not more than 12.4 percent I-125 and not more than 0.4 percent Te-121. The ratio of the concentration of I-123 and I-125 changes with time. Graph 1 shows the minimum concentration of I-123 as a function of time and Graph 2 shows the maximum concentration of I-125 as a function of time.
  • Graph 1. Radionuclidic Concentration of I-123
  • Arrayn- Array
  • Graph 2. Radionuclidic Concentration of I-125
  • Arrayn- Array
  • Sodium iodide I-123 is readily absorbed from the upper gastrointestinal tract. Following absorption, the iodide is distributed primarily within the extracellular fluid of the body. It is trapped and organically bound by the thyroid and concentrated by the stomach, choroid plexus and salivary glands. It is excreted by the kidneys.
  • The fraction of the administered dose which is accumulated in the thyroid gland may be a measure of thyroid function in the absence of unusually high or low iodine intake or administration of certain drugs which influence iodine accumulation by the thyroid gland. Accordingly, the patient should be questioned carefully regarding previous medications and/or procedures involving radiographic media. Normal subjects can accumulate approximately 10 to 50% of the administered iodine dose in the thyroid gland, however, the normal and abnormal ranges are established by individual physician's criteria. The mapping (imaging) of sodium iodide I-123 distribution in the thyroid gland may provide useful information concerning thyroid anatomy and definition of normal and/or abnormal functioning of tissue within the gland.
  • Administration of Sodium Iodide I 123 Capsules is indicated as a diagnostic procedure to be used in evaluating thyroid function and/or morphology.
  • To date there are no known contraindications to the use of Sodium Iodide I 123 Capsules.
  • Females of childbearing age and pediatric patients should not be studied unless the benefits anticipated from the performance of the test outweigh the possible risk of exposure to the amount of ionizing radiation associated with the test.
  • No data
  • Although rare, reactions associated with the administration of sodium iodide isotopes for diagnostic use include, in decreasing order of frequency, nausea, vomiting, chest pain, tachycardia, itching skin, rash and hives.
  • The recommended oral dose for the average patient (70 kg) is 3.7 to 14.8 MBq (100 to 400 u03bcCi). The lower part of the dosage range 3.7 MBq (100 u03bcCi) is recommended for uptake studies alone, and the higher part 14.8 MBq (400 u03bcCi) for thyroid imaging. The determination of I-123 concentration in the thyroid gland may be initiated at six hours after administering the dose and should be measured in accordance with standardized procedures.
  • The patient dose should be measured by a suitable radioactivity calibration system immediately prior to administration. The capsules can be utilized up to 30 hours after calibration time and date. Thereafter, discard the capsules in accordance with standard safety procedures. The user should wear waterproof gloves at all times when handling the capsules or container.
  • The estimated absorbed radiation doses to several organs of an average patient (70 kg) from oral administration of the maximum dose of 14.8 MBq (400 u03bcCi) of I-123 are shown in Table 4 for thyroid uptakes of 5, 15, and 25%. For comparison at these three values of thyroid uptake, the estimated radiation doses from doses of 3.7 MBq (100 u03bcCi) I-131, also used as thyroid imaging agent, are also included.
  • Catalog Number 601,602.
  • Sodium Iodide I 123 is supplied as capsules for oral administration in strengths ofu00a03.7 MBq (100 u00b5Ci) (red and white) (NDC 69945-601-10) and 7.4 MBq (200 u00b5Ci) (green and white) (NDC 69945-602-20) at time of calibration. Each gelatin capsule contains sucrose as a filler. The capsules are packaged in plastic vials containing one capsule of a single strength per vial. The plastic vial is packaged in a lead shield. A package insert is supplied with each lead shield.
  • The contents of the vial are radioactive and adequate shielding and handling precautions must be maintained.
  • Dispense and preserve capsules in tightly-closed containers that are adequately shielded. Store at controlled room temperature 20u00b0 to 25u00b0C (68u00b0 to 77u00b0F).
  • Storage and disposal of Sodium Iodide I 123 Capsules should be controlled in a manner that is in compliance with the appropriate regulations of the government agency authorized to license the use of this radionuclide.
  • Curium and the Curium logo are trademarks of a Curium company.u00a92018 Curium US LLC. All Rights Reserved.
  • Manufactured by: Curium USu00a0LLC Maryland Heights, MO 63043
  • Made in USA
  • A601I0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0
  • R12/2018
  • CURIUMu2122
  • Sodium Iodide I 123 Capsulesn DIAGNOSTICFor Oral Administration OnlyStore at Controlled Room Temperature20u00ba to 25u00b0C (68u00ba to 77u00b0F)n- Rx only
  • WARNING:n- CURIUMu2122n- CAUTION RADIOACTIVE MATERIAL
  • R12/2018
  • Sodium Iodide I 123 Capsulesn DIAGNOSTICFor Oral Administration OnlyStore at Controlled Room Temperature20u00ba to 25u00b0C (68u00ba to 77u00b0F)n- Rx onlyn- WARNING:n- CAUTION RADIOACTIVE MATERIAL
  • CURIUMu2122

Ask for Quote

GNH India is WHO GDP and ISO 9001 2015 Certified Pharmaceutical Wholesaler, Supplier, Exporters from India of sodium iodide i 123 (SODIUM IODIDE I 123) which is also known as SODIUM IODIDE I 123 and Manufactured by Curium US LLC. It is available in strength of 100 uCi/1.

sodium iodide i 123 (SODIUM IODIDE I 123) is supplied for Tenders, Emergency imports, Un - licensed, Specials, Orphan drug, Name patient line, RLD supplies, Reference listed drugs, Comparator Drug, Bio-Similar, Innovator samples, For Clinical trials. Click to know price.

Browse Our Services And Processes

Name Patient Supply

Name Patient Supply

Validated Cold Chain Shipment

Validated Cold Chain Shipment

Comparator Sourcing for Clinical Trials

Comparator Sourcing for Clinical Trials

Our Process - The Gnh Way

Our Process - The Gnh Way

Other Pharmaceutical Products

desogestrel and ethinyl estradiol (EMOQUETTE)

desogestrel and ethinyl estradiol (EMOQUETTE)

Liposomal Amphotericin - B for Injection IP (AmBisome)

Liposomal Amphotericin - B for Injection IP (AmBisome)

Beclomethasone Dipropionate and Levosalbutamol Inhaler (Aerocort)

Beclomethasone Dipropionate and Levosalbutamol Inhaler (Aerocort)

Monobenzone Cream USP 20% (Albaquin)

Monobenzone Cream USP 20% (Albaquin)

Melphalan Injection IP 50mg (Alkacel)

Melphalan Injection IP 50mg (Alkacel)

Edatate Calcium Disodium Injection USP 200mg/ml (Cal-Rsodate)

Edatate Calcium Disodium Injection USP 200mg/ml (Cal-Rsodate)

Are you an existing customer or a vendor of GNH India? Log in here to